These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 7751583)

  • 21. Changes in serum fibrogenesis markers during interferon therapy for chronic hepatitis type C.
    Ishibashi K; Kashiwagi T; Ito A; Tanaka Y; Nagasawa M; Toyama T; Ozaki S; Naito M; Azuma M
    Hepatology; 1996 Jul; 24(1):27-31. PubMed ID: 8707274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Longitudinal evaluation of a fibrosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin.
    Trocme C; Leroy V; Sturm N; Hilleret MN; Bottari S; Morel F; Zarski JP
    J Viral Hepat; 2006 Oct; 13(10):643-51. PubMed ID: 16970595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum WFA(+) -M2BP is a non-invasive liver fibrosis marker that can predict the efficacy of direct-acting anti-viral-based triple therapy for chronic hepatitis C.
    Ura K; Furusyo N; Ogawa E; Hayashi T; Mukae H; Shimizu M; Toyoda K; Murata M; Hayashi J
    Aliment Pharmacol Ther; 2016 Jan; 43(1):114-24. PubMed ID: 26503582
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histologic changes in liver biopsy specimens produced by recombinant interferon alpha-2b therapy for chronic non-A,non-B viral hepatitis. A randomized controlled trial.
    David E; Pucci A; Palladin D; Saracco G; Garello E; Pintus C; Rocca G; Chiandussi L; Solinas A; Mollo F
    Am J Clin Pathol; 1992 Oct; 98(4):397-401. PubMed ID: 1415021
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of interferon treatment for patients with chronic hepatitis C: comparison of response in cirrhotics, fibrotics, or nonfibrotics.
    Everson GT; Jensen DM; Craig JR; van Leeuwen DJ; Bain VG; Ehrinpreis MN; Albert D; Joh T; Witt K
    Hepatology; 1999 Jul; 30(1):271-6. PubMed ID: 10385666
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum hyaluronan and laminin level in children with chronic hepatitis B during long-term lamivudine treatment.
    Lebensztejn DM; Skiba E; Sobaniec-Lotowska ME; Kaczmarski M
    Hepatogastroenterology; 2007; 54(75):834-8. PubMed ID: 17591074
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effect of interferon alpha on liver fibrosis in patients with chronic hepatitis B].
    Yu H; Cao ZC; Geng JY; He ZG; Wang ZM; Sun XY; Wang ZH
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Nov; 25(11):1409-12. PubMed ID: 16305968
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Post-prandial serum hyaluronan concentration in patients with chronic liver disease.
    Idobe Y; Murawaki Y; Ikuta Y; Koda M; Kawasaki H
    Intern Med; 1998 Jul; 37(7):568-75. PubMed ID: 9711881
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum hyaluronic acid and laminin as biomarkers in liver fibrosis.
    Parsian H; Rahimipour A; Nouri M; Somi MH; Qujeq D; Fard MK; Agcheli K
    J Gastrointestin Liver Dis; 2010 Jun; 19(2):169-74. PubMed ID: 20593050
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship between serum concetrations of type III procollagen, hyluronic acid and histopathological findings in the liver of HCV-positive blood donors.
    Camacho VR; Silveira TR; Oliveira JR; Barros SG; Cerski CT
    Arq Gastroenterol; 2007; 44(2):118-22. PubMed ID: 17962855
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: impact of bilharziasis and fibrosis stage.
    Derbala MF; Al Kaabi SR; El Dweik NZ; Pasic F; Butt MT; Yakoob R; Al-Marri A; Amer AM; Morad N; Bener A
    World J Gastroenterol; 2006 Sep; 12(35):5692-8. PubMed ID: 17007024
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of serum IFN-λ3 with inflammatory and fibrosis markers in patients with chronic hepatitis C virus infection.
    Aoki Y; Sugiyama M; Murata K; Yoshio S; Kurosaki M; Hashimoto S; Yatsuhashi H; Nomura H; Kang JH; Takeda T; Naito S; Kimura T; Yamagiwa Y; Korenaga M; Imamura M; Masaki N; Izumi N; Kage M; Mizokami M; Kanto T
    J Gastroenterol; 2015 Aug; 50(8):894-902. PubMed ID: 25501286
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pilot study of recombinant human alpha-interferon for chronic non-A, non-B hepatitis.
    Kakumu S; Arao M; Yoshioka K; Ichimiya H; Murase K; Aoi T; Kusakabe A
    Am J Gastroenterol; 1989 Jan; 84(1):40-5. PubMed ID: 2521421
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A detailed analysis of the Knodell score and other histologic parameters as predictors of response to interferon therapy in chronic hepatitis C.
    Banner BF; Barton AL; Cable EE; Smith L; Bonkovsky HL
    Mod Pathol; 1995 Apr; 8(3):232-8. PubMed ID: 7542385
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interferon and prednisone therapy in chronic hepatitis C with non-organ-specific antibodies.
    Calleja JL; Albillos A; Cacho G; Iborra J; Abreu L; Escartín P
    J Hepatol; 1996 Mar; 24(3):308-12. PubMed ID: 8778197
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis.
    Everson GT; Balart L; Lee SS; Reindollar RW; Shiffman ML; Minuk GY; Pockros PJ; Govindarajan S; Lentz E; Heathcote EJ
    Aliment Pharmacol Ther; 2008 Apr; 27(7):542-51. PubMed ID: 18208570
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HCV viraemia is more important than genotype as a predictor of response to interferon in Sicily (southern Italy).
    Magrin S; Craxi A; Fabiano C; Marino L; Fiorentino G; Lo Iacono O; Volpes R; Di Marco V; Almasio P; Vaccaro A; Urdea MS; Wilber JC; Bonura C; Gianguzza F; Capursi V; Filiberti S; Stuyver L; Pagliaro L
    J Hepatol; 1996 Nov; 25(5):583-90. PubMed ID: 8938531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of hepatitis G virus infection on the severity of liver disease and response to interferon-alpha in patients with chronic hepatitis C.
    Martinot M; Marcellin P; Boyer N; Detmer J; Pouteau M; Castelnau C; Degott C; Aupérin A; Collins M; Kolberg J; Wilber J; Benhamou JP; Erlinger S
    Ann Intern Med; 1997 Jun; 126(11):874-81. PubMed ID: 9163288
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of response to combined interferon alpha-2b and ribavirin therapy in patients of chronic hepatitis c with serum alanine aminotransferase levels and severity of the disease on liver biopsy.
    Nadeem A; Hussain MM; Aslam M; Hussain T; Butt IF; Ali Khan S; Asad A
    J Ayub Med Coll Abbottabad; 2009; 21(2):103-6. PubMed ID: 20524482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.